Evidence map›Paper›PMID 41287734›Full record

ArticleCureus2025

A Rare Presentation of Guillain-Barré Syndrome: A Case Report and Literature Review.

Ivonne De la Hoz, Grayson White, Mohamad Sharbatji

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ivonne De la HozInternal Medicine, AdventHealth Orlando, Orlando, USA.
Grayson WhiteInternal Medicine, AdventHealth Orlando, Orlando, USA.
Mohamad SharbatjiInternal Medicine, AdventHealth Orlando, Orlando, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guillain-Barré syndrome (GBS) is a term that includes a group of autoimmune-mediated peripheral neuropathies affecting varying nerve distributions, typically characterized by an acute onset of areflexic paralysis with albumino-cytologic dissociation. Given the wide range of subtypes and clinical presentations, GBS can be difficult to diagnose; however, the life-threatening nature of the disorder makes prompt diagnosis and treatment a top priority. A 36-year-old athletic young male with a history of recent upper respiratory infection presented to the emergency department complaining of difficulty walking. He initially developed numbness in his genital and perianal area, followed by tingling in his hands and feet, and then difficulty walking due to unsteadiness, which ultimately prompted him to seek medical attention. His blood pressure was 142/85 mmHg, and his heart rate was 58 bpm. The initial physical exam revealed hyporeflexia and ataxic gait, while no deficits were observed in the cranial nerves, and the motor strength was intact in all four extremities. The following day, right-sided facial paralysis and proximal lower extremity weakness (able to move against only minimal resistance) were noted. Due to a strong suspicion of GBS, a five-day course of intravenous immunoglobulin (IVIG) was started. By the following day, the patient showed areflexia with worsening proximal lower extremity weakness and proximal upper extremity weakness. Cerebrospinal fluid (CSF) analysis showed albumin-cytologic dissociation. The total protein was elevated while the cell count was normal, findings consistent with GBS. By hospital day four, facial diplegia was evident, though notably, without any oculomotor involvement. In addition, he had developed dysarthria and dysphagia. The weakness in the lower extremities continued to progress, ultimately restricting movement only to instances when gravity was counterbalanced. Fortunately, the patient did not exhibit any signs of respiratory compromise, and both vital capacity (VC) and negative inspiratory force (NIF), which were carefully monitored, remained within normal limits. Upon completion of the IVIG course, the patient did not show any new neurologic deficits; instead started to show slow improvement in motor function. He continued to engage in intensive physical and occupational therapy and was eventually discharged to an inpatient rehab facility, where gradual improvement continued. This patient exhibited a unique constellation of symptoms, combining features of classic GBS and rarer variants, posing a true diagnostic challenge. This case was marked by ataxia, facial diplegia, and paresthesia, in addition to the hallmark ascending weakness, highlighting the clinical complexity. GBS is a life-threatening condition; therefore, early recognition is crucial. Patients need close cardiac and respiratory monitoring as they are at risk for autonomic dysfunction and respiratory compromise. Treatment options include plasmapheresis and IVIG, and both therapies are equivalent and should be started rapidly.

Indexed as

acute inflammatory demyelinating polyneuropathy (aidp)bickerstaff's brainstem encephalitis (bbe)facial diplegiagait ataxiaguillain-barré syndromemiller fisher syndrome (mfs)polyneuropathy

Identifiers

PMID41287734
PMCPMC12640570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.